Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring

While most patients with chronic myeloid leukemia (CML) express either e13a2 or e14a2 BCR-ABL1 transcripts, a significant minority expresses variant transcripts, of which e19a2 is the most common. Although considered to have a relatively favourable outcome, reported responses to tyrosine kinase inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Langabeer, Stephen E., McCarron, Sarah L., Kelly, Johanna, Krawczyk, Janusz, McPherson, Suzanne, Perera, Kanthi, Murphy, Philip T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420773/
https://www.ncbi.nlm.nih.gov/pubmed/22937329
http://dx.doi.org/10.1155/2012/458716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420773/
https://www.ncbi.nlm.nih.gov/pubmed/22937329
http://dx.doi.org/10.1155/2012/458716

Ejemplares similares